Johnson & Johnson Family of Companies
2622 articles with Johnson & Johnson Family of Companies
Johnson & Johnson to Host Investor Conference Call on First-Quarter Results - March 15, 2023
Johnson & Johnson will host a conference call for investors at 8:30 a.m. on Tuesday, April 18th to review first-quarter results.
Johnson & Johnson Announces Pricing of $7.75 Billion of Senior Notes Issued by Kenvue Inc.
Johnson & Johnson announced that Kenvue Inc., a wholly owned subsidiary of Johnson & Johnson, priced an offering of the following series of senior unsecured notes in an aggregate principal amount of $7.75 billion.
Zhongchao Inc. Renews Partnership with Johnson & Johnson (China)
Zhongchao Inc. announced the renewal of the partnership between Zhongchao Medical Technology Co., Ltd., of which Zhongchao consolidates the operations and financial results through a series of contractual arrangements and Johnson & Johnson Investment Limited.
Fresh off of his Sanofi exit, John Reed is joining Johnson & Johnson, where he will serve as executive vice president, pharmaceuticals, R&D.
Johnson & Johnson to Participate in the Barclays Global HealthCare Conference
Johnson & Johnson will participate in the Barclays Global HealthCare Conference on Tuesday, March 14th, at the Loews Miami Beach Hotel, Miami Beach, Florida.
Johnson & Johnson Names Paula A. Johnson, President of Wellesley College, to its Board of Directors
Johnson & Johnson announced that Paula A. Johnson, MD, MPH, President of Wellesley College, has been appointed to its Board of Directors.
Johnson & Johnson Appoints Dr. John Reed as Executive Vice President, Pharmaceuticals, R&D
Johnson & Johnson announced the appointment of John Reed, M.D., Ph.D., to the Company’s Executive Committee as Executive Vice President of Pharmaceuticals, R&D.
Ankyra Therapeutics Announces Collaboration to Evaluate ANK-101 in Early Clinical Trials Focused on Lung Cancer
Ankyra Therapeutics today announced that is has entered into a strategic collaboration with the Lung Cancer Initiative (LCI) at Johnson & Johnson*.
Johnson & Johnson to Participate in the Cowen 43rd Annual HealthCare Conference
Johnson & Johnson will participate in the Cowen 43rd Annual HealthCare Conference on Tuesday, March 7th, at the Boston Marriott Copley Place, Boston, MA.
Bronwyn Brophy is appointed new CEO of Vitrolife AB (publ)
Bronwyn Brophy is Irish and has extensive experience of leading positions in Global Life Science and Medtech companies such as Thermo Fisher Scientific, Medtronic and Johnson & Johnson.
Johnson & Johnson Reports Q4 and Full-Year 2022 Results
Johnson & Johnson (NYSE: JNJ) today announced results for fourth-quarter and full year 2022.
Johnson & Johnson discontinued the Phase III trial of an investigational HIV vaccine regimen Wednesday after an independent review showed it was ineffective at preventing disease.
Thursday, Fate Therapeutics announced it terminated the 2020 collaboration agreement with Johnson & Johnson’s biopharma subsidiary Janssen.
Johnson & Johnson Announces Quarterly Dividend for First Quarter 2023
Johnson & Johnson announced that its Board of Directors has declared a cash dividend for the first quarter of 2023 of $1.13 per share on the company’s common stock.
Johnson & Johnson to Host Investor Conference Call on Fourth-Quarter 2022 Results
Johnson & Johnson will host a conference call for investors at 8:30 a.m. on Tuesday, January 24th to review fourth-quarter results.
Johnson & Johnson to Participate in the 41st Annual J.P. Morgan Healthcare Conference
Johnson & Johnson (NYSE: JNJ) will participate in the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9th, at the Westin St. Francis in San Francisco, CA.
Johnson & Johnson announced it was acquiring all outstanding shares of Abiomed for $16.6 billion to expand Abiomed's cardiovascular technologies and increase patient access.
The FDA has greenlit the use of Johnson & Johnson’s Tecvayli in heavily pretreated adult patients with relapsed or refractory multiple myeloma.
Johnson & Johnson will lay off 64 employees from its Manhattan-based pharmaceutical supplies business in the early part of 2023.
Backed by Pfizer, Merck KGaA and J&J, Nucleome Therapeutics secured £37.5 million (about $42.16 million) in an oversubscribed Series A financing round.